结外NK/T细胞淋巴瘤鼻型患者B症状与EBV‐DNA及细胞因子预后价值分析

doi:10.3760/cma.j.cn113030-20220406-00125

Abstract
Figure/Table
References(20)
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To investigate the association of plasma EBV‐DNA copy number, serum cytokines and B symptoms in patients with extranodal natural killer/T‐cell lymphoma, nasal type (ENKTL), unravel the mechanism and assess the prognostic value of clinical indicators. Methods Clinical data of 173 newly‐diagnosed ENKTL patients (116 male, 57 female; median age: 43, 4 to 71 years)were retrospectively analyzed. According to Ann Arbor stage, 126 cases were classified as stage I‐II and 47 cases of stage Ⅲ‐IV. The primary sites of tumors included nasal cavity (n=100), extranasal upper aerodigestive tract (extranasal UADT, n=34), and extra‐upper aerodigestive tract (extra‐UADT, n=39). Prior to treatment, 91 patients had B symptoms and 82 cases of without B symptoms. According to plasma EBV‐DNA copy levels, all patients were divided into the negative group (n=36), low load group (<10⁴ copies/ml, n=73) and high load group (≥10⁴ copies/ml, n=64). Serum cytokines including IFN‐γ, IL‐2, IL‐4, IL‐6, IL‐10 and TNF‐α were detected. Correlation analysis was performed by Cochran‐Armitage trend test and Spearman correlation analysis. Survival analysis was conducted using univariate and multivariate Cox regression hazard analysis and survival curves were derived from Kaplan‐Meier survival analysis. Results The incidence of B symptoms and fever showed a significant upward trend with the increasing plasma EBV‐DNA copy levels. In addition, serum levels of IFN‐γ, IL‐6 and IL‐10 cytokines were higher in patients with B symptoms than those without B symptoms (all P<0.05). Serum IFN‐γ, IL‐6, and IL‐10 levels were also positively correlated with plasma EBV‐DNA copy number. The occurrence of B symptoms was associated with high‐risk clinical features including advanced stage, primary tumor invasion, regional lymph node involvement, and elevated pre‐treatment LDH. Survival analysis showed that stage, B symptoms, plasma EBV‐DNA, and the above serum cytokines affected the prognosis of overall survival (OS) and progression‐free survival (PFS) (all P<0.05). However, multivariate analysis showed that the occurrence of B symptoms was not an independent prognostic factor of ENKTL patients. Conclusion This exploratory study suggests that the incidence of B symptoms is associated with increasing levels of EBV‐DNA copies and cytokines, and these indicators are also important factors influencing the prognosis of ENKTL patients.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Zhang Yuetong
	Zhang Yujing
	Wang Jijin
	Shao Han
	Wang Hanyu
	Dai Shuqin
	Huang Huiqiang

Key words： NK/T cell lymphoma B symptoms Plasma EBV‐DNA Serum cytokine Prognosis

Received: 06 April 2022

Corresponding Authors: Zhang Yujing, Email: zhangyj@sysucc.org.cn

Cite this article:

Zhang Yuetong,Zhang Yujing,Wang Jijin et al. Association of plasma EBV‐DNA copy number and cytokines with B symptoms in patients with extranodal natural killer/T‐cell lymphoma, nasal type[J]. Chinese Journal of Radiation Oncology, 2022, 31(8): 704-709.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20220406-00125 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2022/V31/I8/704

[1] Fox CP, Civallero M, Ko YH, et al.Survival outcomes of patients with extranodal natural‐killer T‐cell lymphoma: a prospective cohort study from the international T‐cell project[J]. Lancet Haematol, 2020,7(4): e284‐e294.DOI: 10.1016/S2352‐3026(19)30283‐2.
[2] Tse E, Kwong YL.The diagnosis and management of NK/T‐cell lymphomas[J]. J Hematol Oncol, 2017,10(1): 85.DOI: 10.1186/s13045‐017‐0452‐9.
[3] Lee J, Suh C, Park YH, et al.Extranodal natural killer T‐cell lymphoma, nasal‐type: a prognostic model from a retrospective multicenter study[J]. J Clin Oncol, 2006,24(4): 612‐618.DOI: 10.1200/JCO.2005.04.1384.
[4] Kwong YL, Pang AW, Leung AY, et al.Quantification of circulating Epstein‐Barr virus DNA in NK/T‐cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance[J]. Leukemia, 2014,28(4): 865‐870.DOI: 10.1038/leu.2013.212.
[5] Cohen JI, Jaffe ES, Dale JK, et al.Characterization and treatment of chronic active Epstein‐Barr virus disease: a 28‐year experience in the United States[J]. Blood, 2011,117(22): 5835‐5849.DOI: 10.1182/blood‐2010‐11‐316745.
[6] Rong Q, Gao Y, Cai Q, et al.High IL‐6 expression in the tumor microenvironment is associated with poor prognosis of patients with extranodal natural/killer T‐cell lymphoma(ENKTL)[J]. Expert Rev Anticancer Ther, 2021,21(1): 121‐127.DOI: 10.1080/14737140.2021.1853531.
[7] Bao C, Zhou D, Zhu L, et al.Increased serum level of interleukin‐6 correlates with negative prognostic factors in extranodal NK/T‐cell lymphoma[J]. Transl Cancer Res, 2020,9(4): 2378‐2389.DOI: 10.21037/tcr.2020.03.49.
[8] Qi SN, Xu LM, Yuan ZY, et al.Effect of primary tumor invasion on treatment and survival in extranodal nasal‐type NK/T‐cell lymphoma in the modern chemotherapy era: a multicenter study from the China Lymphoma Collaborative Group(CLCG)[J]. Leuk Lymphoma, 2019,60(11): 2669‐2678.DOI: 10.1080/10428194.2019.1602265.
[9] Bothra SJ, Bhandari P, Agrawal N, et al.Extranodal NK‐T cell lymphoma, nasal type: retrospective analysis of real‐world data[J]. Indian J Hematol Blood Transfus, 2020,36(2): 260‐266.DOI: 10.1007/s12288‐019‐01195‐6.
[10] Lee J, Cho SG, Chung SM, et al.Retrospective analysis of treatment outcomes for extranodal NK/T‐cell lymphoma(ENKL), nasal type, stage Ⅰ‐ⅡE: single institute experience of combined modality treatment for early localized nasal extranodal NK/T‐cell lymphoma(ENKL)[J]. Ann Hematol, 2013,92(3): 333‐343.DOI: 10.1007/s00277‐012‐1630‐z.
[11] 牛绍清,张玉晶,杨勇,等.早期原发鼻腔与韦氏环NK/T细胞淋巴瘤临床特征和预后比较[J]. 中华放射肿瘤学杂志,2013,22(5): 352‐356.DOI: 10.3760/cma.j.issn.1004‐4221.2013.05.004.
Niu SQ, Zhang YJ, Yang Y, et al.Comparison of clinical features and prognosis between patients with early‐stage NK/T‐cell lymphoma originating from nasal cavity and Waldeyer's ring[J]. Chin J Radiat Oncol, 2013,22(5): 352‐356.DOI: 10.3760/cma.j.issn.1004‐4221.2013.05.004.
[12] Fei Q, Tian XK, Wu J, et al.Prognostic significance of Epstein‐Barr virus DNA in NK/T‐cell lymphoma: a meta‐analysis[J]. Onco Targets Ther, 2018,11:997‐1004.DOI: 10.2147/OTT.S153942.
[13] 王朝阳,李晔雄.结外鼻型NK/T细胞淋巴瘤与游离EB病毒DNA拷贝数研究进展[J]. 中华放射肿瘤学杂志,2010,19(2): 166‐169.DOI: 10.3760/cma.j.issn.1004‐4221.2010.02.026.
Wang CY, Li YX.Research progress on extranodal nasal NK/T cell lymphoma and cell‐free Epstein‐Barr virus DNA copy number[J]. Chin J Radiat Oncol, 2010,19(2): 166‐169.DOI: 10.3760/cma.j.issn.1004‐4221.2010.02.026.
[14] Jorgovanovic D, Song M, Wang L, et al.Roles of IFN‐γ in tumor progression and regression: a review[J]. Biomark Res, 2020,8:49.DOI: 10.1186/s40364‐020‐00228‐x.
[15] Evans SS, Repasky EA, Fisher DT.Fever and the thermal regulation of immunity: the immune system feels the heat[J]. Nat Rev Immunol, 2015,15(6): 335‐349.DOI: 10.1038/nri3843.
[16] Hasday JD, Thompson C, Singh IS.Fever, immunity,molecular adaptations[J]. Compr Physiol, 2014,4(1): 109‐148.DOI: 10.1002/cphy.c130019.
[17] Conti B, Tabarean I, Andrei C, et al.Cytokines and fever[J]. Front Biosci, 2004,9:1433‐1449.DOI: 10.2741/1341.
[18] Saraiva M, Vieira P, O'Garra A, et al.Biology and therapeutic potential of interleukin‐10[J]. J Exp Med, 2020,217(1).DOI: 10.1084/jem.20190418.
[19] Lee CH, Yeh TH, Lai HC, et al.Epstein‐Barr virus Zta‐induced immunomodulators from nasopharyngeal carcinoma cells upregulate interleukin‐10 production from monocytes[J]. J Virol, 2011,85(14): 7333‐7342.DOI: 10.1128/JVI.00182‐11.
[20] Ohga S, Nomura A, Takada H, et al.Dominant expression of interleukin‐10 and transforming growth factor‐beta genes in activated T‐cells of chronic active Epstein‐Barr virus infection[J]. J Med Virol, 2004,74(3): 449‐458.DOI: 10.1002/jmv.20197.